Everolimus retroaldol degradation product

CAS : 1708118-13-1

Ref. 3D-ITC11813

Informations sur le produit

• Nom: Everolimus retroaldol degradation product
• Marque: Biosynth
• Description: Everolimus is a drug that is used in the treatment of certain cancers. It acts by binding to the cytosolic protein receptor known as the mammalian target of rapamycin (mTOR). This binding causes the inhibition of mTOR. Everolimus is converted by enzymes into a number of metabolites, including the retroaldol degradation product. The retroaldol degradation product has been shown to bind to ion channels and inhibit their activity. It is also a ligand for several receptors, such as the peptide growth hormone releasing factor (GHRF) receptor.

Propriétés chimiques

• Masse moléculaire: 958.2 g/mol
• Formule: C₅₃H₈₃NO₁₄
• Degré de pureté: Min. 95%